News and Updates

Breakthrough T1D was there when the top type 1 diabetes (T1D) experts from all over the world convened this month at the American Diabetes Association’s (ADA) Scientific Sessions in San Francisco, which was held June 7-11. Breakthrough T1D played the key roles of presenter, educator and active learner—and was the key funder and supporter of […]

The ADA’s Scientific Sessions is completed! Here, with the post-day recap, is Marlon Pragnell, Ph.D., head of the complications program at Breakthrough T1D, with a recap of type 1 diabetes complications research and results from the ADA conference:

Two leading innovators in the type 1 diabetes (T1D) space have announced a collaborative partnership aimed at enabling those with T1D to select favorite devices, knowing they all work together, even if made by different companies. The nonprofit company Tidepool announce that it is partnering with leading pump manufacturer Medtronic to create an interoperable automated […]

The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immune therapy program at Breakthrough T1D, who highlights some of the important immune-based therapies and what they mean for the type 1 diabetes community:

There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here is Jessica Dunne, Ph.D., senior director of the prevention portfolio, who gives a recap of day in T1D prevention research:

A new artificial pancreas system that both doses and takes away insulin is showing critical benefits in helping those with type 1 diabetes maintain more consistent, and healthier, glucose levels. Two studies, shared this weekend, showed that the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology by Tandem® Diabetes Care resulted in more […]

There was some really amazing results out here in San Francisco! Here is Dan Finan, Ph.D., head of the Breakthrough T1D’s artificial pancreas and glucose control programs, to recap the day:

This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated a significant delay in the time to onset of type 1 diabetes (T1D) in high-risk relatives of people with the disease. A significant delay meaning 2+ years! This is the first ever study […]

We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from Breakthrough T1D‘s assistant director for science, Andy Rakeman, Ph.D.:

The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement therapies. Happy viewing!